| Basics |
Exelixis, Inc. Common Stock
Exelixis Inc is a biotechnology company. It is involved in discovery, development, and commercialization of new medicines for people with cancer. The Cabometyx product generates maximum revenue for the company.
|
| IPO Date: |
May 1, 2000 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$10.96B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.26 | 2.19%
|
| Avg Daily Range (30 D): |
$0.59 | 1.40%
|
| Avg Daily Range (90 D): |
$0.52 | 1.31%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
2.06M |
| Avg Daily Volume (30 D): |
2.23M |
| Avg Daily Volume (90 D): |
2.04M |
| Trade Size |
| Avg Trade Size (Sh.): |
156 |
| Avg Trade Size (Sh.) (30 D): |
59 |
| Avg Trade Size (Sh.) (90 D): |
58 |
| Institutional Trades |
| Total Inst.Trades: |
12,213 |
| Avg Inst. Trade: |
$2.95M |
| Avg Inst. Trade (30 D): |
$4.88M |
| Avg Inst. Trade (90 D): |
$5.29M |
| Avg Inst. Trade Volume: |
.16M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$7.04M |
| Avg Closing Trade (30 D): |
$18.89M |
| Avg Closing Trade (90 D): |
$18.97M |
| Avg Closing Volume: |
331.05K |
|
|
| Financials |
| |
TTM |
Q3 2026 |
Q2 2026 |
|
Basic EPS
|
|
$.72
|
$.68
|
|
Diluted EPS
|
|
$.69
|
$.65
|
|
Revenue
|
$
|
$ 597.76M
|
$ 568.26M
|
|
Gross Profit
|
$
|
$ 579.18M
|
$ 548.79M
|
|
Net Income / Loss
|
$
|
$ 193.58M
|
$ 184.85M
|
|
Operating Income / Loss
|
$
|
$ 236.54M
|
$ 213.58M
|
|
Cost of Revenue
|
$
|
$ 18.57M
|
$ 19.47M
|
|
Net Cash Flow
|
$
|
$ 211.87M
|
$ -19.32M
|
|
PE Ratio
|
|
|
|
|
|
|
